NPS PHARMS INC
BiotechNPS PHARMS INC is a biotechnology company focused on Metabolic. Key products include NATPARA.
NPS PHARMS INC's Key Drugs
NPS PHARMS INC's core commercial portfolio centers on NATPARA, spanning Metabolic — its most strategically important drugs approved in the last 15 years.
NPS PHARMS INC's Recent FDA Approvals
New NDA/BLA approvals for NPS PHARMS INC over the last two years — novel drugs only, excluding generics and label supplements.
NPS PHARMS INC's Therapeutic Areas
NPS PHARMS INC's approved drugs and pipeline span 1 therapeutic area, led by Metabolic, across 1 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
NPS PHARMS INC's Top Competitors
NPS PHARMS INC's closest competitors by therapeutic-area and drug-target overlap include Merck, Baxter, and Johnson & Johnson. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
NPS PHARMS INC Pipeline Snapshot
Active clinical trials for NPS PHARMS INC across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • NATPARA leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Metabolic pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2015-01-23
- Latest
- 2022-04-07
- Applications
- 1